Share chart Chemomab Therapeutics Ltd.
Extended chart
Simple chart
About Chemomab Therapeutics Ltd.
Chemolab Therapeutics Ltd., биотехнологическая компания клинической стадии, открывает и разрабатывает терапевтические средства для лечения фиброзных и воспалительных заболеваний. Ведущим клиническим продуктом компании является CM-101, гуманизированное моноклональное антитело, прошедшее фазу 2a клинических испытаний, которое препятствует основной функции растворимого хемокина CCL24 для лечения первичного склерозирующего холангита (ПСХ) и системной склеродермии (ССД). Ранее компания называлась Anchiano Therapeutics Ltd., а в марте 2021 года сменила название на Chemob Therapeutics Ltd.IPO date | 2019-02-12 |
---|---|
ISIN | US16385C1045 |
Industry | Biotechnology |
Sector | Health Care |
Валюта | usd |
Валюта отчета | usd |
Сайт | https://www.chemomab.com |
Цена ао | 1.39 |
Change price per day: | 0% (1.39) |
---|---|
Change price per week: | +11.2% (1.25) |
Change price per month: | -30.85% (2.01) |
Change price per 3 month: | -12.03% (1.58) |
Change price per half year: | -19.88% (1.735) |
Change price per year: | +73.9% (0.7993) |
Change price per 3 year: | -66.9% (4.2) |
Change price per 5 year: | +6.11% (1.31) |
Change price per 10 year: | 0% (1.39) |
Change price per year to date: | -23.2% (1.81) |
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
Institutions | Volume | Share, % |
---|---|---|
Orbimed Advisors LLC. | 2241274 | 0 |
Cormorant Asset Management, LP | 288169 | 15.66 |
Ikarian Capital, LLC | 236709 | 12.87 |
KESTRA PRIVATE WEALTH SERVICES, LLC | 31241 | 1.7 |
Two Sigma Investments, LP | 30263 | 1.65 |
BOOTHBAY FUND MANAGEMENT, LLC | 26529 | 1.44 |
Two Sigma Advisers, LP | 11800 | 0.64 |
Geode Capital Management, LLC | 11737 | 0.64 |
Advisory Services Network, LLC | 11173 | 0.61 |
Morgan Stanley | 7800 | 0.42 |
Head | Job title | Payment | Year of birth |
---|---|---|---|
Dr. Adi Mor George Ph.D. | Co-Founder, Chief Scientific Officer, CEO & Executive Director | 435.4k | 1982 (43 years) |
Barbara Lindheim | Consulting Vice President of Investor & Public Relations, Strategic Communications | N/A | |
Dr. Matthew B. Frankel M.B.A., M.D. | Chief Medical Officer & VP of Drug Development | N/A | 1969 (56 years) |
Ms. Sigal Fattal CPA, M.B.A. | Chief Financial Officer | 258k | 1971 (54 years) |
Mr. Jack Lawler | Senior VP of Global Clinical Development Operations |
Address: Israel, Tel Aviv, Building 7 - open in Google maps, open in Yandex maps
Website: https://www.chemomab.com
Website: https://www.chemomab.com